公开(公告)号：US20190248857A1

公开(公告)日：2019-08-15

申请号：US16387123

申请日：2019-04-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/725 ,  A61P35/00 ,  C12N5/0783 ,  C07K16/30 ,  C12N15/10 ,  G01N33/574 ,  A61K39/00 ,  C12N15/115 ,  C07K14/74

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K39/001102 ,  A61K2039/5158 ,  A61K2039/572 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2818 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0638 ,  C12N15/1062 ,  C12N15/115 ,  C12N2501/50 ,  G01N33/57492

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190055302A1

公开(公告)日：2019-02-21

申请号：US16178674

申请日：2018-11-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C12N15/115 ,  A61K39/00 ,  G01N33/574 ,  C12Q1/6881 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/47 ,  A61K38/00 ,  A61K35/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190010198A1

公开(公告)日：2019-01-10

申请号：US16026707

申请日：2018-07-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/74 ,  C07K16/30 ,  C07K14/725 ,  C12N5/0783 ,  G01N33/574 ,  C12N15/10 ,  A61K39/00 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190002504A1

公开(公告)日：2019-01-03

申请号：US16100858

申请日：2018-08-10

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K39/00 ,  C07K7/06 ,  C12N5/0783 ,  C12N9/64 ,  A61K38/17

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20180282393A1

公开(公告)日：2018-10-04

申请号：US16009301

申请日：2018-06-15

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C12Q1/6886 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C12N5/0783 ,  G01N33/574 ,  C07K16/28 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/635 ,  C07K14/7051 ,  C07K16/2833 ,  C07K2319/70 ,  C12N5/0638 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57484

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170260249A1

公开(公告)日：2017-09-14

申请号：US15451167

申请日：2017-03-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens Fritsche ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K14/725 ,  C12Q1/68 ,  A61K39/00 ,  C12N15/115 ,  C07K16/28 ,  A61K35/17

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K38/00 ,  A61K38/1709 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/2833 ,  C07K2319/70 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6881 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/57484 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170189511A1

公开(公告)日：2017-07-06

申请号：US15375047

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/38 ,  C07K14/725 ,  C07K14/81 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170189504A1

公开(公告)日：2017-07-06

申请号：US15374415

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/28 ,  C07K14/725 ,  C07K14/71 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G16B25/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.